On December 22, 2023, the China Non-prescription Drug Association announced the "2023 Comprehensive Statistical Ranking of China's Non-prescription Drug Products" in Beijing, in which Mandi was rated as the first chemical drug product for the first time. It is worth noting that the previous champions of this category were often firmly occupied by common drugs against infectious diseases such as Daknin and Baiduobang. Mandi is the ace drug for hair loss, and the core ingredient is minoxidil tincture, which is also the first time that this class of drugs has reached the top.
Mandi's ascent to the top this time indicates that a larger hair loss economic market is emerging. With the continuous improvement of residents' living standards and the transformation of labor and production methods, more and more consumers have begun to pay attention to hair health and personal image management. Combined with Mandi's outstanding performance in the OTC chemical drug category list in recent years, it is not difficult to see that users prefer to choose external drugs represented by Mandi in the face of various ** solutions such as anti-hair loss shampoo, hair transplantation, hair maintenance, and drugs**, which is not only for the sake of popularity, user reputation and convenience of operation, but also highlights the essential demands of users for hair growth efficacy and drug safety.
Promotion] Disclaimer: The content of this article is this **publication or **corporate promotional information, which only represents the author's personal views and has nothing to do with this website. It is for readers' reference only, and please verify the relevant content on your own. ）